Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
173 hedge funds and large institutions have $3.76B invested in Mirati Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 86 increasing their positions, 45 reducing their positions, and 44 closing their positions.
102% more call options, than puts
Call options by funds: $111M | Put options by funds: $55M
91% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 45
9% less funds holding
Funds holding: 190 → 173 (-17)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
32% less capital invested
Capital invested by funds: $5.5B → $3.76B (-$1.74B)
34% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$102M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$67.9M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
+$40M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$38.1M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$36.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$38.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$38.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$18.6M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$14M |
| 5 |
Morgan Stanley
New York
|
-$10.3M |
MRTX Hedge Fund Activity: Q1 2020 in Review
173 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2020, worth a combined $3.76B — down 32% from $5.5B a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of MRTX and 29 opened new positions — a net loss of 15 holders — while 45 trimmed existing stakes and 86 added.
The largest buyer was Wellington Management Group, adding an estimated $102M. The largest seller was Invesco, cutting an estimated $38.8M.
- 173 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2020, down from 190 in Q4 2019.
- Funds reported $3.76B of Mirati Therapeutics, Inc. Common Stock stock for Q1 2020, down 32% quarter-over-quarter.
- 29 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2020 and 44 closed out, a net change of -15 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2020 was Wellington Management Group, an estimated $102M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2020 was Invesco, an estimated $38.8M sold.
Based on aggregated 13F filings for Q1 2020.